Bailard’s Neurocrine Biosciences NBIX Stock Holding History

Bailard’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,900	Closed	-$374K	–	723
2020 Q4	$374K	Hold	3,900	–	–	0.02%	392
2020 Q3	$375K	Hold	3,900	–	–	0.02%	343
2020 Q2	$476K	Hold	3,900	–	–	0.03%	276
2020 Q1	$338K	Hold	3,900	–	–	0.02%	288
2019 Q4	$419K	Sell	3,900 -1,000	-20%	-$105K	0.02%	337
2019 Q3	$442K	Hold	4,900	–	–	0.03%	292
2019 Q2	$414K	Hold	4,900	–	–	0.03%	331
2019 Q1	$432K	Hold	4,900	–	–	0.03%	334
2018 Q4	$350K	Hold	4,900	–	–	0.02%	388
2018 Q3	$602K	Hold	4,900	–	–	0.04%	324
2018 Q2	$481K	Hold	4,900	–	–	0.03%	376
2018 Q1	$406K	Sell	4,900 -2,000	-29%	-$169K	0.03%	372
2017 Q4	$535K	Buy	+6,900	New	+$471K	0.03%	305

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Bailard's NBIX Position: Q1 2021 in Review

Bailard sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 3,900 shares — an estimated $374K sold.

Bailard first reported a position in NBIX in Q4 2017 and held it in 13 quarters. The position peaked at $602K in Q3 2018. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

Bailard reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
Bailard sold 3,900 Neurocrine Biosciences shares in Q1 2021, an estimated $374K.
Bailard first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 13 quarters.
Bailard's Neurocrine Biosciences position peaked at $602K in Q3 2018.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Bailard's 13F filing for Q1 2021, filed 13 May 2021.